4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry.

Allergy Asthma Clin Immunol · 2017 · PMC5530516 · PMID 28769983

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

described that the ACQ score significantly decreased from 3.58 ± 1.28 to 2.01 ± 1.05 after 16 weeks (−43.7%), treatment responders showed greater and highly significant improvements of symptoms compared with non-responders even after 16 weeks (−46.9%, p < 0.0001 vs −36.1%, p < 0.05) [ 16 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.